---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-003717"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:55:53.558251+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors

## Summary
- Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.
- Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.
- Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.
- Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed.

## SEC filing metadata
- accession: 0001628280-26-003717
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/0001628280-26-003717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/pcrx-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-003717
- JSON: https://secwatch.observer/filing/0001628280-26-003717.json
- Plain text: https://secwatch.observer/filing/0001628280-26-003717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.